Thrivent Financial for Lutherans Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Thrivent Financial for Lutherans reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 3.1% in the third quarter, Holdings Channel.com reports. The firm owned 9,548 shares of the medical equipment provider’s stock after selling 302 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Hologic were worth $778,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter worth approximately $25,000. Innealta Capital LLC purchased a new stake in shares of Hologic in the 2nd quarter valued at $25,000. Sunbelt Securities Inc. purchased a new position in Hologic in the 2nd quarter worth $37,000. Cromwell Holdings LLC lifted its stake in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the last quarter. Finally, Cranbrook Wealth Management LLC purchased a new stake in Hologic during the second quarter valued at about $47,000. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HOLX. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Raymond James raised their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Finally, UBS Group increased their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $77.47 on Wednesday. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The stock has a market capitalization of $17.58 billion, a P/E ratio of 23.26, a P/E/G ratio of 2.49 and a beta of 0.96. The company’s 50-day moving average is $80.13 and its 200 day moving average is $78.52. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the company earned $0.89 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.